OXB is a specialist gene and cell therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining its own proprietary therapeutic candidates. Above service-fees, OXB will receive royalties on commercial products developed with its LentiVector® platform: extensive IP, facilities, and know-how for production and development of lentiviral vectors to generate gene-based therapies. OXB intends to out-license its five clinical candidates
31 Mar 2017
Delivering commercial gene-therapy vector
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Delivering commercial gene-therapy vector
Oxford BioMedica plc (OXB:LON) | 219 3.3 0.7% | Mkt Cap: 218.8m
- Published:
31 Mar 2017 -
Author:
Martin Hall -
Pages:
52
OXB is a specialist gene and cell therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining its own proprietary therapeutic candidates. Above service-fees, OXB will receive royalties on commercial products developed with its LentiVector® platform: extensive IP, facilities, and know-how for production and development of lentiviral vectors to generate gene-based therapies. OXB intends to out-license its five clinical candidates